Jamison Private Wealth Management Inc. Boosts Stock Holdings in Danaher Co. (NYSE:DHR)

Jamison Private Wealth Management Inc. increased its stake in Danaher Co. (NYSE:DHR) by 1.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,756 shares of the conglomerate’s stock after acquiring an additional 159 shares during the period. Jamison Private Wealth Management Inc.’s holdings in Danaher were worth $2,239,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC raised its stake in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after purchasing an additional 148,251 shares during the period. Fisher Asset Management LLC lifted its position in Danaher by 2.6% during the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after buying an additional 116,299 shares during the period. Massachusetts Financial Services Co. MA grew its position in shares of Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares during the period. Finally, Montrusco Bolton Investments Inc. increased its stake in shares of Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after acquiring an additional 397,671 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

Shares of Danaher stock opened at $245.95 on Friday. The stock’s fifty day moving average is $235.33 and its 200 day moving average is $253.45. Danaher Co. has a one year low of $225.42 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a market cap of $177.65 billion, a P/E ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is 20.61%.

Analysts Set New Price Targets

A number of brokerages have weighed in on DHR. UBS Group decreased their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research note on Thursday, October 31st. Stephens restated an “overweight” rating and set a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Finally, KeyCorp raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.